We are international
Donate
• IMF TV TEXT SIZE   
#Ask Dr. Durie

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
previous     next      view all

12.18.14   #AskDrDurie: What does IMWG’s new diagnostic criteria mean for myeloma patients?

In this episode of #AskDrDurie, Dr. Brian Durie talks about the new diagnostic guidelines and tests that can be used to diagnose myeloma early, before CRAB features have emerged. These criteria have been published in a new publication available on myeloma.org.


12.10.14   #AskDrDurie: Why wasn’t panobinostat approved?

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a  patient's question about why the recent FDA ODAC hearing rejected the use of new drug panobinostat for myeloma. He also discusses other HDAC inhibitors that are currently in development.


12.03.14   #AskDrDurie: What's new at ASH 2014

In this week’s special #AskDrDurie episode, Dr. Brian Durie of the IMF takes a look at the December 2014 ASH (American Society of Hematology) meeting in San Francisco. He previews what abstracts will be presented and talks about news to expect out of the meeting.


11.19.14   #AskDrDurie: Can Cytoxan cause heart damage?

In this week's #AskDrDurie, the IMF's Dr. Brian G.M. Durie answers a patient's concern regarding myeloma treatment and heart damage--specifically when it comes to the drug Cytoxan.


11.13.14   #AskDrDurie: What happens to stem cells once they are harvested?

In this week's episode of #AskDrDurie, Dr. Brian G.M. Durie of the IMF answers a patient's question regarding stem cells. If they are harvested in a specific facility, can they be moved and stored elsewhere later?
 
Find out the answer in this video!


11.06.14   #AskDrDurie: Can the Hevylite™ test be used to monitor IgA myeloma?

In this week’s episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a patient question regarding IgA myeloma and tests used to monitor it, specifically the Hevylite™ test. Watch this video to learn all about Hevylite.


10.30.14   #AskDrDurie: Is it possible to have short remissions without high-risk features?

Inspired by last week's #AskDrDurie episode in which Dr. Brian Durie of the IMF explained the definition of remission when it comes to  myeloma patients, this new episodes is a follow-up. Here, Dr. Durie explains why a myeloma patient might experience a short remission period, even if high-risk features have not been identified.


10.23.14   #AskDrDurie: What is remission?

In the latest episode of #AskDrDurie, Dr. Brian Durie of the IMF explains what remission means for myeloma patients.


10.16.14   #AskDrDurie: How does the IMF contribute to the myeloma community?

In the latest episode of #AskDrDurie, Dr. Brian Durie addresses a patient who has just learned about the IMF by explaining three key contributions the IMF makes to myeloma research and education.


09.25.14   #AskDrDurie: What is Selinexor

In this week's episode of #AskDrDurie, Dr. Brian Durie of the IMF takes a question from a patient who has relapsing myeloma and is wondering about the new drug Selinexor. Dr. Durie explains what the drug is and how it can be used in myeloma.


previous     next      view all